Tofacitinib Benefits and Risks

Mechanism and Indications

• Tofacitinib is used with caution in patients over 65 or with cardiovascular risk factors due to increased risks of serious adverse events including thrombosis, malignancy, and cardiovascular events, as recommended by the American Gastroenterological Association 1

Benefits

• The American College of Gastroenterology recommends tofacitinib for maintaining remission in ulcerative colitis with high certainty evidence for large benefit in both 5mg and 10mg twice daily doses 2, 1
• Tofacitinib has comparable efficacy to biologic DMARDs, including TNF inhibitors, in rheumatoid arthritis, as stated by the American College of Rheumatology 3
• The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis notes that tofacitinib has administration advantages, including oral administration and no immunogenicity issues, making it a preferred option for some patients 4, 5

Risks and Safety Concerns

• The American Heart Association warns that tofacitinib increases the risk of major adverse cardiovascular events (MACE) and cancer compared to TNF inhibitors in RA patients over 50 with cardiovascular risk factors 1, 3
• The European Medicines Agency cautions that JAK inhibitors, including tofacitinib, should only be used when no suitable alternatives are available in patients aged 65 years or above, those at increased risk of cardiovascular problems, current or long-term past smokers, and those at increased risk of cancer 2, 5, 1
• The American College of Cardiology notes that tofacitinib has a five-fold increase in pulmonary embolus for patients on 10mg twice daily compared to TNF inhibitor therapy 4

Regulatory Considerations and Recommendations

• The FDA recommends that tofacitinib requires prior failure of or contraindications to TNF antagonists before use, as stated by the American Gastroenterological Association 6
• The European Medicines Agency recommends that doses should be reduced in patients at risk of VTE, cancer, or cardiovascular problems, as noted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis 1

Monitoring Recommendations

• The American Academy of Dermatology recommends screening for tuberculosis, hepatitis, and HIV before initiating tofacitinib therapy 7
• The Centers for Disease Control and Prevention suggest considering zoster vaccination before starting tofacitinib therapy in those aged over 70 years and those over 50 years at high risk, as recommended by the American College of Physicians 4

Tofacitinib Clinical Use and Safety

Mechanism of Action and Dosing

• Tofacitinib preferentially inhibits JAK1 and JAK3, interrupting the JAK/STAT signaling pathway critical for inflammatory cytokines, and can be used as monotherapy or in combination with methotrexate 8, 9
• In patients with moderate to severe renal impairment, the dose should be reduced to 5 mg once daily 8, 9
• In patients with moderate hepatic impairment, the dose should be reduced to 5 mg once daily, and it is not recommended in patients with severe hepatic impairment 8, 9

Drug Interactions and Safety

• Tofacitinib should be avoided during any active serious infection, and patients treated with tofacitinib should be on at least prophylactic dose anticoagulation when used for severe conditions 8, 9, 10
• Live vaccines are contraindicated once tofacitinib is started 8, 9
• Tofacitinib can be used with methotrexate and corticosteroids, but should not be combined with potent immunosuppressants, biologics used for inflammatory diseases, or tocilizumab or other IL-6 inhibitors 8, 9, 10

Special Considerations

• Use of tofacitinib is recommended only if potential benefit justifies potential risk to the fetus, and pregnancy test is required in all patients of childbearing potential before initiation 8, 9
• Hold tofacitinib until hemoglobin values normalize if anemia develops 8

Tofacitinib Safety and Contraindications

Regulatory Black‑Box Warnings

• The FDA has issued four black‑box warnings for tofacitinib covering serious infections (including tuberculosis and opportunistic pathogens), increased mortality, venous thromboembolism, and malignancies such as lymphoma. 11

Required Safety Precautions

• Patients treated with tofacitinib should receive at least prophylactic‑dose anticoagulation, especially when the drug is used for severe inflammatory conditions. [11][12]

Infection Screening Requirements

• Reactivation of latent tuberculosis is a recognized risk; mandatory tuberculosis screening (e.g., IGRA or tuberculin skin test) must be performed before initiating tofacitinib. 11

Adverse Event Data from COVID‑19 Trials

• In randomized COVID‑19 trials, tofacitinib was associated with a higher incidence of serious adverse events (relative risk = 1.18; 95 % CI 0.64–2.15). [11][12]

Absolute Contraindications

• Active serious infections, active tuberculosis, and a personal history of current or prior thrombosis are absolute contraindications to tofacitinib therapy. 11

Trial Exclusion Criteria (High‑Risk Populations)

• Individuals with a personal or first‑degree family history of clotting disorders were excluded from pivotal tofacitinib trials. [11][12]
• Patients with immunosuppression, active malignancy, or significant cytopenias (e.g., low lymphocyte, neutrophil, hemoglobin, or platelet counts) should not receive tofacitinib. [11][12]

Drug‑Drug Interaction Restrictions

• Co‑administration of tofacitinib with IL‑6 inhibitors such as tocilizumab (or other biologic DMARDs) is contraindicated due to additive immunosuppression risk. [11][12]